Also found in: Medical.
PSTIPatient Specific Therapeutic Interchange
PSTIPrecise Software Technologies Inc (software developers; Ottawa, Ontario, Canada; est. 1989)
PSTIPetroleum Science and Technology Institute (UK)
PSTIPS Technologies, Inc.
PSTIPrivate Sector Training Institutions (vocational training; various locations)
PSTIPublic Sector Training Institution (Singapore)
PSTIPersonal Safety Training Inc (Spokane, WA)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The Figure shows conserved PstI restriction profiles obtained for the A/[C.sub.2] plasmids that are different from those exhibited by the I1 plasmids.
Adapters were ligated by means of 1U T4 DNA ligase (Promega), 1x T4 DNA ligase buffer, 5 pmol PstI or EcoRI adaptor, and 50 pmol MseI adaptor (Table 2).
The product was 489 by long and, depending on the allele considered, was cut into two fragments of 368 by and 121 bp by the PstI enzyme (c2) or into two fragments of 354 by and 135 bp by the RsaI enzyme (c1).
A double restriction enzyme digestion of 0.5 mg total genomic DNA [1x One-Phor-All Buffer (OPA) (Pharmacia), 5 U PstI or EcoRI (Promega, Madison, WI, and Life Technologies, Inc., Gaithersburg, MD, respectively), 5 U MseI (New England Biolabs, Inc., Beverly, MA), 5 mg BSA; 50 mL total volume] was incubated for 3 h at 37 [degrees]C.
In the present study, allele frequencies of G[right arrow]A, PstI, and HincII polymorphisms did not differ between the two groups.
* Pluristem Therapeutics Inc.(NASDAQ: PSTI) rose 7.1% to close at $5.42.
(PSTI) significantly improve cardiac function in mice with induced diabetes.
RFLP with PstI and BglII showed only one band each of 5.6 kb and 8 kb, respectively, in four of the 1998 O139 strains (PG265, PG269, PG316, and PG351), while the 1992 O139 strain (SG24) exhibited two bands of sizes 7.0 and 5.6 and 8.0 and 7.0 kb, respectively (Table 3).
The TVMV-PVY NIa fusion was created by engineering a PstI site in the 3' primer for TVMV-NIa.
* Pluristem Therapeutics Inc.(NASDAQ: PSTI) climbed 11.7% to close at $5.06.
Food and Drug Administration (FDA) has granted fast track designation to Pluristem Therapeutics' (PSTI) ongoing Phase 3 study of PLX PAD cells for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization.